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An approach to the delineation and identification of cell surface molecules
shared between different tissues involves the generation of antibodies to one cell
type and testing their reactivity with antigens from a second. Such an approach
has been of value in the identification of differentiation molecules of immuno-
logical and neurological importance . There exist on neuronal and lymphoid cell
types many common cell surface antigens including Thy-1 (1), T/Tn (2), class I
histocompatability antigens (3), CALLA (4), acetylcholine receptor (5), myelin
basic protein (6), HNK-1 (7), OKT6 (8), OKT9 (8), UCHT1 (9), and la (3).
These shared antigens may reflect similar patterns of gene expression and
membrane interactions by these two cell types. Some shared antigens may be
important to interactions between the nervous and immune systems (10) .
We have used rabbit anti-peripheral blood mononuclear cells (RAPBMC)'
sera to examine cell surface molecules on lymphocytes and neuronal cells with
common antigenic determinants. The crossreactive cell surface molecules on
human lymphocytes and the human neuronal cell line, SK-N-SH, identified by
these heteroantisera, have been found to be remarkably restricted to a single
complex of proteins. These molecules were found to be identical to the very late
activation antigen (VLA) molecules, recently described glycoproteins defined by
mAbs A-IA5 and TS2/7. The first mAb precipitates a 130,000 Mr protein from
resting T cells and complexes composed of 200,000Mr, 160,000 Mr, and 130,000
M,- components from mitogen- or alloantigen-stimulated human T cells (11-14).
In unactivated circulating lymphocytes, there is ample expression of the 130,000
M, chain, but much less of the 160,000 and 180,000 Mr chains. The activation-
specific mAb TS2/7 does not react with those resting T cells, but precipitates
200,000 M, and 130,000 M, components from activated T lymphocytes. The
VLA complexes are heterodimers composed of 130,000 Mr common 0 subunits
associated with either a 200,000 M, a' subunit or a 160,000 M, a2 subunit (14).
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￿
2D, two-dimensional; NRS, normal rabbit serum; RABR,rabbit
anti-brain; RAPBMC, rabbit anti-PBMC; SAC, Staphylococcus aureus Cowan I strain; TLCK, N-a-p-
tosyl-L-lysyl chloromethyl ketone; TPCK, L-1-tosylamide-2-phenylethyl chloromethyl ketone; VLA,
very late activation antigen.
J. Exp. MED. © The Rockefeller University Press - 0022-1007/86/08/0393/14$1 .00
￿
393
Volume 164 August 1986 393-406394 LEUKOCYTE-NEURONAL CROSSREACTIVE ACTIVATION ANTIGENS
Materials and Methods
Antibodies.
￿
The mAb A-IA5 and TS2/7, anti-VLA monoclonals (11) were the gener-
ous gift ofDr . Martin Hemler (The Dana-Farber Cancer Institute, Boston, MA). RAPBMC
001 and 005 were raised by immunization of rabbits with 10' Ficoll-Hypaque isolated
human PBMC in CFA, by multiple subcutaneous and intramuscular injections. Boosts
were performed at 4-wk intervals with 5 .0 x 10' PBMCs in IFA, and blood was obtained
before each immunization by earbleeding. RAPBMC 021 and 022 were similarly prepared
except the PBMCs were centrifuged three times at low speed (150 g) for 10 min to remove
platelets before immunization . Sera were stored at -80°C, and complement-inactivated
by heating to 56°C for 30 min before use. Rabbit anti-human brain (RABR) sera 017
and 018 were similarly prepared, except that the immunogen was normal human cerebral
cortex obtained at autopsy (3 h postmortem). Cortex was homogenized with a tight-fitting
Dounce and washed three times in saline by centrifugation at 300 g. 1 ml of a 50% vol/vol
suspension was emulsified with an equal volume of IFA and injected in multiple subcuta-
neous and intramuscular locations. Boosts with the same immunogen were performed at
monthly intervals. RABR sera 0 .19 and 020 were prepared by immunization with 1 ml
of partially purified human brain membrane prepared as detailed below . Rabbits were
boosted at 6 mo and bled at 13 mo.
Mouse anti-human PBMC sera were prepared by immunization of BALB/c mice with
2.0 x 10' human PBMCs without adjuvant i.p., and boosting at 3 wk and 8 mo with 10'
PBMCs, followed by individual tail vein bleeding, complement-inactivation of sera, and
storage at -80'C.
Neuronal Cells.
￿
The neuronal cell line SK-N-SH (15) was obtained from Dr. June Lee
Biedler (Sloan Kettering Memorial Cancer Center, Rye, NY), and passaged as monolayer
cells in MEM with 20% FCS as previously described (16). Before use, the cells were
trypsinized and washed twice with MEM, and cultured overnight to allow reexpression of
surface antigens in a serum-free medium (N 1) consisting of MEM containing insulin (5
mg/liter), transferrin (50 mg/liter), progesterone (0.006 mg/liter), putrescine (0.016
ing/liter), Na2SeOs (0.005 mg/liter), L-Gln (2 mM), nonessential amino acids (20 ml/liter),
penicillin 100,000 (U/liter), and streptomycin (100,000 ug/liter).
Lymphocyte Preparations.
￿
PBMCs were obtained by Ficoll-Hypaque (Pharmacia Fine
Chemicals, Piscataway, NJ) density gradient centrifugation (17), and washed three times
with RPMI. These were further processed by passage through a nylon wool column (18)
to yield nylon wool T-enriched cells (T cells) before iodination.
Radiolabelling.
￿
T cells were externally iodinated by a modification of the method of
Baur et al. (19). To 5 x 10' cells in 500 ul PBS were added I mCi Na"5I (New England
Nuclear, Boston, MA) and 10 ul lactoperoxidase (B grade, 100 IU/ml ; Calbiochem-
Behring, San Diego, CA) and 25 ul of 0.03% H202. After 5 min, 5,u] of lactoperoxiclase
were added and 10 ul of 0.03% H202 were added at 5 and 10 min . After 15 min, the
reaction was stopped by the addition of cold RPMI, and cells were washed six times with
medium . Viability was >95% before and after iodination, as judged by trypan blue
exclusion.
SK-N-SH neuronal cells were cultured overnight in N 1 serum-free medium at 37'C,
washed twice with medium and once with HBSS containing 1 mM CaCl2 and 0.5 mM
MgC12, then cell surface-iodinated at 22'C by the addition of 1 ml HBSS containing Ca"
and Mg", 50 At lactoperoxidase, 0.5 mCi Na"5I, and 25 At of 0.03% H202. At 5 min, an
additional 25 At of lactoperoxidase and 10 At of 0.03% H202 were added. After 10 min
the monolayers were washed six times with MEM .
Extraction and Immunoprecipitation.
￿
Cells were lysed and complexes were isolated as
previously described (20, 21). Cells were lysed in 0 .15 M NaCl, 0 .01 M Tris pH 7 .4, 0 .5%
NP-40 (TBS-NP-40) containing 0.06 mM N-a-p-tosyl-L-lysyl chloromethyl ketone (TLCK)
(Sigma Chemical Co., St. Louis, MO), 0 .06 MM L-1-tosylamide-2-phenylethyl chloromethyl
ketone (TPCK) (Sigma Chemical Co.), and 0 .2 mm PMSF (Sigma Chemical Co.) for 30
min at 4°C. Lysates were ultracentrifuged at 100,000 g for 30 min at 4°C, and aliquots
were precleared by incubation with 100 At of 10% Sansorbin (Staphylococcus aureus lacking
protein A; Calbiochem-Behring) for 15 min, followed by centrifugation (Microfuge B;PISCHEL ET AL.
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Beckman Instruments, Palo Alto, CA) for 4 min. Antibodies were either added to intact
cells before lysis or to the detergent-solubilized lysates after preclearance, and were
allowed to bind for 30 min at 4°C. The immune complexes were collected with 50 Al of
10% Staphylococcus aureus Cowan strain I (SAC) (Calbiochem-Behring) and washed six
times with TBS-NP-40. Washed pellets were eluted and denatured with 50 UI 1% SDS
and 5% 2-ME br heating at 100°C for 2 min, and analyzed by 8% Laemmli SDS-PAGE
(22) along with 'C-labeled markers: myosin (200,000 Mr), phosphorylase B (92,000 M,),
BSA (68,000 M,), ovalbumin (45,000 Mr), chymotrypsin (25,000 Mr), ,6-lactoglobulin
(18,400 M,), and cytochrome c (12,400 Mr) (Bethesda Research Laboratories, Gaithers-
burg, MD). Gels were fixed and stained with 0.5% Coomassie Brilliant Blue (Bio-Rad
Laboratories, Richmond, CA), destained with 10% acetic acid, 10% 2-isopropyl alcohol,
then dried and autoradiographed with prefogged XR-5 film (Eastman Kodak, Rochester,
NY) using an intensifying screen (Cronex Lighting-Plus, Dupont Co., Wilmington, DE)
for 1-30 d at -80°C.
Two-dimensional (2D) PAGE.
￿
2D-PAGE was carried out after the method of O'Farrell
(23). Samples were eluted from the SAC immunoadsorbent by incubation with 8 M urea
and 5% 2-ME for 60 min at 22°C, and applied to prefocused 6% acrylamide tube gels
with 10 mM phosphoric acid and 50 mM Tris electrode solutions. They were then focused
for 10 h at 1,000 V. The gels were equilibrated with SDS-PAGE diluent buffer containing
2-ME, run on 8% SDS-PAGE, and processed as described above for 1D SDS-PAGE.
Neuronal Membrane Preparation and Iodination.
￿
Neuronal membrane was prepared
from human brain by the method of Rodman and Akeson (24) . Histopathologically
normal brain tissue, obtained at autopsy, was minced, washed in cold saline, and homog-
enized using a tight-fitting Dounce with 10 ml of homogenization buffer composed of
0.32 M sucrose, 25 mM Tris HCI, 0.06 mM TPCK, 0.06 mM TLCK, 0 .2 mM PMSF,
and 10 mM iodoacetamide. Iodoacetamide was included to minimize brain protein
disulfide crosslinking, which otherwise occurs in brain homogenates (unpublished obser-
vation). The homogenate was centrifuged at 2,000 g for 5 min, the pellet was rehomog-
enized in 10 ml homogenization buffer, and then recentrifuged at 2,000 g for 5 min. The
resultant supernatants were pooled and recentrifuged at 10,000 g for 15 min to pellet
particulate matter. The remaining supernatant was adjusted to be 0.8 mM Ca" and 0 .5
mM Mg". A membrane-enriched fraction was then obtained by 100,000 g centrifugation
for 20 min. The neuronal membrane-enriched pellet was suspended in 0.5 ml PBS and
iodinated by the initial addition of 20 1AI lactoperoxidase, 1 mCi Na'211, and 50 Al of
0.03% H202, followed by 10 Al lactoperoxidase and 12 ji1 of 0 .03% H202 at 5 and 10
min. At 15 min, the sample was diluted to 10 ml with PBS and membrane-pelleted by
100,000 g centrifugation for 20 min. The pellet was suspended in PBS, and repelleted by
two rounds of centrifugation . This membrane fraction was solubilized by addition of 5 ml
of TBS-NP-40 with vigorous vortexing, and after 30 min, any insoluble material was
removed by ultracentrifugation for 20 min at 100,000 g. The supernatant was frozen at
-80°C until used for immunoprecipitation.
Results
RAPBMC Sera React Predominantly with Three Molecules on SK-N-SH Neuronal
Cells, which Comigrate with VLA Crossreactive Molecules. We used RAPBMC to
analyze the pattern of crossreactive surface molecules on neuronal cells. The
human neuronal cell line SK-N-SH was cell surface-iodinated, and molecules
reactive with RAPBMC, RABR, or mAb A-IA5 (VLA a chain-specific) were
precipitated from TBS-NP-40 lysates. The resultant precipitates were separated
by 8% SDS-PAGE and detected by autoradiography (Fig. 1) . Only a few mole-
cules were precipitated by each of the four RAPBMC sera tested (lanes 2-5) .
Each serum precipitated similar bands of M, 180,000, 160,000, and 130,000,
and these bands were more intense than any other bands. These three RAPBMC-
reactive molecules were not detected with four RABR (lanes 6-9) or with normal396
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FIGURE 1 .
￿
Immunoprecipitation of RAPBMC-reactive molecules from the SK-N-SH neu-
ronal cell line, and comparison to VLA molecules precipitated with mAb A-IA5 . SK-N-SH
neuronal cells were cell surface-iodinated with lactoperoxidase, extracted with NP-40, and
immunoprecipitated with 5 juI rabbit antisera or 25 p1 ofmAb followed by 501AI of 10% SAC .
Reduced precipitates were run on 8% SDS-PAGE followed by autoradiography . Test antibod-
ies were: lane 1, anti-VLA (A-IA5) ; lanes 2-5, four separate RAPBMC (RaPBM) (001, 005,
021, and 022) ; and lanes 6-9 RABR (RceBR) (017, 018, 019, and 020) . Positions of molecular
markers (M, X 10-s) are shown at left .
rabbit serum (NRS) (not shown) . The RABR sera precipitated a single dominant
band of 140,000Mr not seen with NRS, which migrated between the 130,000
and 160,000Mr molecules precipitated by the RAPBMC sera .
The three RAPBMC-precipitated bands from SK-N-SH cells were similar in
size to the three bands precipitated by mAb A-IA5 (Fig . 1, lane 1), and they
appeared similar in electrophoretic mobility to the reported values of the a', a2 ,
and0VLA chains precipitated by A-IA5 from extracts of activated T cells (11,
14) . This suggested that the neuronal cell line SK-N-SH bears the a' 180,000
M,VLA molecule previously identified only on activatedT cells . It also suggested
that much of the RAPBMC crossreactivity toward SK-N-SH neuronal cells was
directed at VLA molecules .
Sequential Immunoprecipitation Establishes that the Three RAPBMC-precipitated
MoleculesAreVLA Crossreactive. To directly test whether the RAPBMC-reactive
neuronal cell molecules were identical to those recognized by mAb A-IA5,PISCHEL ET AL .
￿
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FIGURE 2 .
￿
Sequential precipitations o£ neuronal lysates showed that RAPBMC clearance
removes VLA-reactive molecules, and that VLA clearance removes the major RAPBMC-
reactive bands . Surface-iodinated SK-N-SH neuronal cell lysates were divided and precleared
with SAC alone (lanes 1-3), or RAPBMC followed by excess SAC (lanes 4-6), or A-IA5
followed by excess SAC (lanes 7-9) . Aliquots were then mixed with theanti-VLA mAbA-IA5
or RAPBMC (001) or RABR (017), and collected with SAC andanalyzed by 8% reduced SDS-
PAGE. Final precipitating reagents were: for lane 1, A-1A5 ; lane 2, RAPBMC ; lane 3, RABR ;
lane 4, A-lA5 ; lane 5, RAPBMC ; lane 6, RABR ; lane 7, A-lA5 ; lane 8, RAPBMC ; and lane
9, RABR . Immunoprecipitates were reduced and run on 8% SDS-PAGE and autoradi-
ographed .
sequential precipitations were performed . Aliquots of lysates from 2 .4 X 10' SK-
N-SH cells were treated with 500,ul A-IA5, 70 ul RAPBMC, or 70 t,l RNS, and
cleared twice with 700 ul of SAC. Each cleared lysate was divided three ways
and tested for residual reactivity with mAb A-IA5, RAPBMC and RABR sera
(Fig . 2) . Three chains were precipitated from the initial lysate by A-IA5 (lane 1)
and RAPBMC (lane 2) . Preclearance with RAPBMC removed the reactivity with
RAPBMC (lane 5), and also removed the A-lA5 reactivity (lane 4) . However
theRABR still precipitated the characteristic 140,000 M, molecule (lane 6) . This
indicated that theRAPBMC preclearance was complete, and that A-IA5-reactive
molecules were all removed by theRAPBMC clearance . The reciprocal clearance
of A-IA5-reactive molecules similarly removed A-IA5 (lane 7) and RAPBMC
reactivities (lane 8), but notRABR target molecules (lane 9) . Thus the antigenic
sites on the high M, molecules recognized by A-1A5 and RAPBMC are expressed
on completely overlapping sets of molecules upon the SK-N-SH cells .398 LEUKOCYTE-NEURONAL CROSSREACTIVE ACTIVATION ANTIGENS
FIGURE 3 . RAPBMC, A-1A5, and TS2/7 precipitated molecules from neuronal cells and
PHA-activated lymphoid cells have similar M, . SK-N-SH neuronal cells (left) and PBMCs
activated with PHA and passed through a nylon wool column (right) were lactoperoxidase
surface-iodinated, and precipitates prepared from lysates using rabbit anti-PBM, the VLA
specific mAbs A-1A5, or TS2/7. Lane 1, SK-N-SH lysate precipitated with RAPBMC (001) ;
lane 2, SK-N-SH lysate precipitated with A-1A5 ; lane 3, SK-N-SH lysate treated with mAb
TS2/7 ; lane 4, activatedT cell lysate precipitated with mAb A-1A5 ; lane 5, activatedT cell
lysate precipitated with mAb TS2-7 . Preparations were analyzed by reduced 8% SDS-PAGE
and autoradiography.
VLA Crossreactive Molecules on Neuronal Cells and VLA Molecules on Activated T
Cells Comigrate and Share a 180,000 Mr Activation-Specific Antigenic Determi-
nant. To determine whether the threeRAPBMC andmAb A-1A5-precipitated
molecules from neuronal cells were similar to VLA-complex chains of activated
Tcells, a side-by-side comparison was made by precipitating lysates from neuronal
cells and from PHA-activatedT cells with RAPBMC and mAb A-1 A5 (Fig . 3) .
A close resemblance was seen between the three A-1A5-precipitated polypeptides
from SK-N-SH (lane 2) and T cells (lane 4) . The sizes of the comparable chains
are very close to one another, although the high Mr component of theT cells
appears to be slightly larger than that of the SK-N-SH cells . The SK-N-SH
RAPBMC-precipitated bands (lane 1) comigrated with those precipitated by A-
IA5 from the neuronal lysates and lymphocyte lysates (lane 4) . However, the
RAPBMC precipitated molecules of various M,. from the activated T cells,
including ones comigrating with VLAand others of different sizes (not shown) .
This indicated that, although the RAPBMC contained immunoprecipitating
antibodies in addition to anti-VLA, only the VLA-like molecules were precipi-
tated from the SK-N-SH neuronal cells .
Although both the activatedT cells and neuronal cells had 180,000Mr chains
associated with their VLA complexes, it was not known whether the neuronal
180,000 M, chain was identical to the 180,000 M, a' chain on activatedT cells
or whether it was a different molecule of similar M, . The 180,000 M, a'
component of the VLA complex contains specificities recognized by a second
mAb, TS2/7, which precipitates 180,000 and 130,000 M, chains from activated
T cells (12, 14). mAb TS2/7 was used to test whether the 180,000 M, chain of
VLA molecules present on neuronal cells contained the activation-specific deter-
minant present on activatedT cells (Fig . 3) . TS2/7 mAb reacted with the SK-N-
SH cell lysate and precipitated two chains (lane 3), which comigrated with thePISCHEL ET AL .
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FIGURE 4 .
￿
2D IEF-PAGE analysis of SK-N-SH neuronal molecules precipitated by RAPBMC
(RaPBM ; b) and VLA precipitated by mAb A-IA5 . SK-N-SH neuronal cells were 1211 Surface-
labeled, extracted with 0.5% NP-40, and immunoprecipitated with mAb A-IA5 (a) and
RAPBMC sera (b) . 2D-PAGE was performed as described by O'Farrell (23) and visualized by
autoradiography. IEF was from left to right, and pIs are shown at bottom . Reduced 8% SDS-
PAGE was from top to bottom, with M, marker positions indicated at left .
180,000 and 130,000 Mr components precipitated by A-IA5 (lane 2) . This
pattern is identical to the two-chain pattern of VLA precipitated by TS2/7 from
activated T lymphocytes (lane 5) . This finding is consistent with the SK-N-SH
neuronal VLA molecules being composed of two forms of heterodimers, one of
180,000/130,000 M, (VLA-1), and the other of 130,000/160,000MT (VLA-2),
as has been proposed for VLA from activatedT lymphocytes (12-14). Since the
180,000 M, VLA chain bears the activation -specific determinant recognized by
mAb TS2/7, and the three VLA chains comigrate, it is likely that the SK-N-SH
and activated T cell VLA 180,000 M, a' polypeptide components are the same .
2D Gel Electrophoresis Indicates that theRAPBMC- and A-IA5-precipitated Chains
from SK-N-SH Have Identical Components . To establish whether the RAPBMC-
and A-IA5-precipitated sets of molecules not only were antigenically indistin-
guishable but molecularly identical, they were analyzed by 2D gel electrophoresis
(Fig . 4) . A-IA5 (a) and RAPBMC (b) immunoprecipitates were prepared from
SK-N-SH neuronal cells, reduced, and focused by the method of O'Farrell for
10 h at 1,000 V, then re-reduced and electrophoresed on 8% SDS-PAGE . The
resultant bands included a strong 130,000 M, 0 chain component with a pl of
4.7 (4.6-5 .0) for both A-IA5 and RAPBMC precipitates . Weaker 130,000 M,.
bands with pIs of 5.4 and 5.9 were also present. The 160,000 M, molecules
focused at pIs of 5.0 and 5 .9 . 180,000M r molecules focused with pl of 5.4 and
5 .9 . The bands of 130,000/160,000/180,000 M, which were observed with400 LEUKOCYTE-NEURONAL CROSSREACTIVE ACTIVATION ANTIGENS
FIGURE 5 . Human brain membrane contains VLA molecules . Normal human brain was
homogenized, anda membrane-rich fraction was prepared by differential centrifugation (24) .
Membrane proteins were iodinated with lactoperoxidase, free "5I was removed, and proteins
solubilized with 0.5% NP-40 . Samples were precleared with SAC, then mAb or serum was
added and immunoreactive molecules were collected with SAC . Lysates were incubated with :
lane 1, no antibody ; lane 2, mAb A-1A5 ; and lane 3, RAPBMC (001) . Immunoprecipitates
were electrophoresed in 8% SDS-PAGE and autoradiographed .
coincident pl of 5 .9 have been less intense in other 2D gels and may represent
incompletely dissociated VLA complexes . The band with pl 5.4 may represent
a newly recognized second 130,000Mr VLA component (see Discussion) . The
2D PAGE patterns of RAPBMC- and A-lA5-precipitated molecules from SK-N-
SH cells closely resembled each other, providing strong evidence that the
antibodies precipitated identical molecules . Neither appeared to purify one subset
of VLA heterodimers preferentially . The lack of additional molecules in the
RAPBMC 2D gel confirms the dominance of theVLA crossreactivity over other
iodinated surface molecules present on SK-N-SH cells .
Normal Brain Tissue Bears VLA Molecules Similar to SK-N-SH, But Not the
180,000 M r Chain .
￿
The expression of VLA molecules on the SK-N-SH cellsPISCHEL ET AL.
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might reflect the normal neuronal phenotype, or it might be an inducible antigen.
Events that might lead to the latter condition include neuroblastoma transfor-
mation and continuous culture in vitro. To determine whether the VLA mole-
cules are present on nontransformed neuronal cells, we prepared a membrane-
rich fraction from human brain tissue and examined it for the presence of VLA
molecules. The membrane preparation was lactoperoxidase-iodinated. Aliquots
were incubated with or withoutantibodies, and reactive moleculeswere collected
with SAC and analyzed by SDS-PAGE (Fig. 5) . The mAb A-IA5 precipitated
specific bands of 130,000 and 160,000 M, (lane 2). The negative control (lane
1) and NRS (not shown) did not precipitate VLA-like molecules. This indicated
that the VLA complex was present in normal brain tissue . However, the 180,000
Mr a' band was not clearly precipitated by the mAb A-IA5 and may not be
present on normal brain tissue. The RAPBMC (lane 3) reacted with several brain
proteins, including two strong bands comigrating with the A-lA5-precipitated
130,000 and 160,000 Mr proteins . The RAPBMC precipitates, other than those
characteristic of VLA, may contain additional antigenic determinants shared by
lymphocytes and brain cell membranes but not by SK-N-SH cells. Alternatively,
preparation of the brain membranes may have exposed internal membrane
proteins that are hidden in intact cells, allowing their iodination and subsequent
detection.
Mouse Anti-PBMCAntisera React Predominantly with VLA Molecules on SK-N-SH
Neuronal Cells. The remarkably restricted RAPBMC heteroantisera crossreac-
tivity with neuronal cells might reflect a specific immune response limited to
rabbits, or it might represent a more general immunological response pattern.
To evaluate thegenerality ofthis restricted crossreactiveresponse, we immunized
mice with human PBMCs and tested individual sera for their patterns of reactivity
on SK-N-SH cells (Fig. 6). Sera from individual PBMC-immunized mice (lanes
2-6) reacted with and precipitated three chains of 180,000, 160,000, and
130,000 Mr, characteristic of the a', a2, and B chains of VLA molecules (lane
7). Normal mouse sera (lane 1) and sera from mice immunized with brain tissue
(not shown) did not precipitate the VLA molecules. This pattern was present in
all five individual mouse anti-PBMC sera analyzed . Thus, the preferential neu-
ronal crossreactivity with the VLA molecules is characteristic of not only rabbits
but also of mice immunized with human PBMCs.
Discussion
RAPBMC sera were found to precipitate three iodinated molecules from SK-
N-SH neuronal cells. These major crossreactive bands migrated at 130,000,
160,000, and 180,000 M, on SDS-PAGE. This limited pattern of crossreactivity
is remarkable, since all three bands were found to be components of VLA, a
mixture of a',# and a'# heterodimers precipitated by mAb A-1A5. The rabbit
anti-PBM heteroantisera contained antibodies to several other iodinatable lym-
phocyte surface antigens. Since electrophoresis of the SK-N-SH neuronal cell
lysates showed many radiolabeled molecules of equal or greater intensity than
the VLA molecules, the preferential precipitation ofthe VLA molecules indicates
that these are thedominant lymphocyte SK-N-SH neuronal cell line crossreactive
antibodies produced by heteroimmunization. One limitation to this interpreta-402
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FIGURE 6 .
￿
Mouse anti-human PBMC antisera (MaPBM) react specifically with VLA mole-
cules from SK-N-SH neuronal cells . Individual sera from mice immunized with human PBMCs
were incubated with surface-iodinated SK-N-SH cell lysates, immune complexes were col-
lected, and characterized by reducedS% SDS-PAGE . Samples were incubated with NMS (lane
1), and mouse anti-PBMC serum (MaPBM) (lanes 2-6) . VLA precipitated with mAb A-IA5
(lane 7) is shown for comparison .
tion is that the technique used would not have detected crossreactive surface
molecules that were not radiolabeled by lactoperoxidase iodination . Normal
brain cell membranesalso contain VLA molecules that react with antilymphocyte
sera, but those sera precipitate proteins of several differentMr in addition to
those characteristic ofVLA . Thus it is clear that VLA is a shared immunogen
on neurons and lymphocytes, but it may not be the major crossreactive molecule,
as suggested by our studies with the SK-N-SH cultured neurons .
The three molecules precipitated by RAPBMC sera from the SK-N-SH have
been identified as VLA molecules by comigration on SDS-PAGE, sequential
clearances, and 2D gel patterns in comparison with precipitates of VLA-specific
mAbs A-IA5 and TS2/7 . The proteins recognized by those mAbs have been
called VLA (very late activation antigens) since the two higher M r chains were
first identified on activatedT cells after 2 wk in culture (11-13) . mAb A-1A5PISCHEL ET AL.
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has been tested for reactivity with many cell types, and precipitates the 130,000
M, ,0 chain either alone or along with the 160,000 Mr a2 chain from several cell
types, but had previously been observed (11) to precipitate a' chains only from
activated T cells and some T cell lines. TS2/7 reacts with the largest of the three
VLA chains (a') on activated T cells (14). Thus VLAjoins the list of differentia-
tion antigens present in a restricted fashion on both neuronal and lymphoid cells.
To precipitate all three of the VLA chains, RAPBMC could react with
determinants on all three chains, but since there is evidence that the 130,000 M,
chain forms dimers with the 160,000 and 180,000 M, chains, the RAPBMC
could react only with the common 130,000 Mr 0 chain, in a way similar to that
of mAb A-IA5 (12, 14). Since the RAPBMC also precipitates the 130,000 Mr (3
chain from unactivated T cells, which contain little of the other two chains, a
major part of RAPBMC reactivity is probably stimulated by and directed at the
130,000 Mr common ,0 chain.
The 180,000 M, VLA a' chain was found on the SK-N-SH cells, but not on
membrane derived from human cortical brain tissue, which, however, had the
130,000 and 160,000 M, chains. This may imply that expression of the high M,.
a' chain of neurons, like that of T cells, is enhanced on actively dividing cells.
The process of malignant transformation that gave rise to the neuroblastomas in
vivo could be responsible for the expression of the a' chain, but its increase on
activated lymphocytes is restricted to T cells and is independent of malignant
transformation (11, 12). Alternatively, the a' chain may be present on normal
neuronal membranes, but it may remain undetected because of its dissociation
from the a chain, or due to destruction during membrane preparation.
Besides providing evidence that the mAb A-IA5 and RAPBMC molecules
precipitated from SK-N-SH are indistinguishable, the 2D gel electrophoresis
patterns of VLA show additional bands not apparent by 1D SDS-PAGE, and
suggest a previously unrecognized feature about the VLA complex. A second
130,000 M, chain with a pI of 5.3 is seen, which may represent another form of
a chain (a3). It appears to be associated with the common VLA 0 chain, since 2D
gels of VLA-precipitates from resting T cells that express very little a' and a2
reveal the 130,000 M, putative as chain. Further experiments will be necessary
to clarify the chain association of the additional component and its relationship
to the a' and a2 components .
The RAPBMC immunological crossreactivity with VLA on SK-N-SH neuronal
cells probably extends to several species, since both RAPBMC sera and mouse
anti-human PBMC sera reacted in similarly restricted fashion with these high
Mr molecules from the SK-N-SH cells. Each individual serum from PBMC-
immunized animals tested showed this preferential reactivity with VLA. Thus,
the dominance of VLA as crossreactive molecules on SK-N-SH neuronal cells
and lymphocytes is not likely to represent an idiosyncratic pattern of a few
individual animals, nor be limited to one species.
Although the VLA molecules are the majortarget recognized by the RAPBMC
sera on SK-N-SH neuronal cells, antisera generated against human brain homog-
enate contained little anti-VLA reactivity. This observation is consistent with
previous findings (25) which showed that major rabbit anti-mouse brain reactiv-
ities in rodent studies are against myelin-associated glycoprotein . This indicates404
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that, although VLA may be very immunogenic on lymphocytes, it is not so within
brain homogenate. It may be that brain antigens such as myelin-associated
glycoprotein are such strong immunogens that a response to the VLA is pre-
vented by means of antigenic competition.
Immunological responses to certain neuronal surface proteins result in autoim-
mune diseases, including demyelinating disorders associated with responses to
myelin-associated glycoprotein (6) and myasthenia gravis associated with antibod-
ies to the acetylcholine receptor (5). Interestingly, each of these crossreactive
molecules is also present on lymphocytes (5, 26). This pattern of autoimmunity
to antigens shared by neuronal and lymphocyte cells may be coincidental, or it
may indicate a pattern of sensitization and crossreactivities that may lead to
autoimmune reactions with normal nervous tissue. Whether these responses are
initially induced by molecules released from neuronal tissue or from lymphocytes
is unknown. Immune responses to VLA have not been studied in detail, but
given theirprominent immunogenicity and their strong neuronal crossreactivity,
they could be important in autoimmune processes involving the nervous system.
It has recently been noted (27) that lymphocytes in the blood and cerebrospinal
fluid of patients with multiple sclerosis contain activated T lymphocytes that also
express the activation-associated chains of VLA. The implications of the close
association of neuronal and lymphocyte VLA molecules await a better under-
standing of the function of VLA.
Summary
The antigenic relationship between human neuronal and lymphocyte cell
surface antigens has been analyzed using heteroantisera raised against human
peripheral blood mononuclear cells (PBMC). The specificities of thecrossreactive
antigens were examined by immunoprecipitation of ' 25I-labeled SK-N-SH cul-
tured neuronal cells using rabbit anti-PBMC (RAPBMC) sera and compared to
known specificities using mAb. The predominant reactivity of each rabbit anti-
serum tested against SK-N-SH cells was with three molecules of 130,000,
160,000, and 180,000 M,.. These three chains comigrated with three molecules
precipitated with the very late activation antigen (VLA)-specific mAb A-IA5.
Sequential precipitations with mAb A-1A5 established that the three RAPBMC-
precipitated bands were members of the VLA complex. This was confirmed by
two-dimensional PAGE of the RAPBMC and A-IA5 immunoprecipitates, which
were indistinguishable from one another. The two-dimensional pattern was more
complex than was anticipated from the heterodimeric model of VLA chain
association, and suggests an additional 130,000 M,. component of VLA. The
three chains of the VLA complex precipitated by RAPBMC or mAb A-IA5
from SK-N-SH neurons closely resembled the VLA pattern present on activated
T cells, including the 180,000 M, activation-specific a' chain recognized by mAb
TS2/7. Normal brain cell membranes also contain VLA molecules that are
precipitated by RAPBMC and mAb A-IA5. Thus the VLA complex provides
potentially important shared immunogens on human neurons and T cells.PISCHEL ET AL.
￿
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